News Releases

2020-11/11
United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpes
1
2020-09/28
COVAXX Initiates Phase 1 Clinical Trial of COVID-19 Vaccine UB-612 in Taiwan
2
2020-08/21
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
3
2020-08/05
United BioPharma Received Approval from Taiwan FDA for a Phase 1 Trial with UB-421 Subcutaneous Formulation in HIV-1 Infected Patients
4
2020-07/13
Dr. Flossie Wong-Staal, a board member of UBI since 1995, passed away on Wednesday, July 8th, at the age of 73 due to pneumonia
5
2020-05/19
Minister of Health and Welfare led the delegation to visit United BioPharma for the COVID-19 vaccine development program
6
2020-04/27
United BioPharma Received Approval from TFDA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
7
2020-03/25
United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy Volunteers
8
2020-03/24
United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV Patients
9
2020-11/11
United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpes
1
2020-09/28
COVAXX Initiates Phase 1 Clinical Trial of COVID-19 Vaccine UB-612 in Taiwan
2
2020-08/21
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
3
2020-08/05
United BioPharma Received Approval from Taiwan FDA for a Phase 1 Trial with UB-421 Subcutaneous Formulation in HIV-1 Infected Patients
4
2020-07/13
Dr. Flossie Wong-Staal, a board member of UBI since 1995, passed away on Wednesday, July 8th, at the age of 73 due to pneumonia
5
2020-05/19
Minister of Health and Welfare led the delegation to visit United BioPharma for the COVID-19 vaccine development program
6
2020-04/27
United BioPharma Received Approval from TFDA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
7
2020-03/25
United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy Volunteers
8
2020-03/24
United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV Patients
9